Detalhe da pesquisa
1.
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10419): 2295-2306, 2023 12 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37931632
2.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 24(3): 286-296, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37052965
3.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol
; 172: 72-77, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36965291
4.
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Br J Cancer
; 127(8): 1479-1486, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35869143
5.
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Int J Gynecol Cancer
; 32(6): 799-803, 2022 06 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35318277
6.
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 267-276, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33539744
7.
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020.
J Transl Med
; 19(1): 144, 2021 04 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33827609
8.
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.
BMC Cancer
; 21(1): 549, 2021 May 14.
Artigo
Inglês
| MEDLINE | ID: mdl-33985435
9.
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system.
Support Care Cancer
; 29(6): 3219-3233, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-33094357
10.
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Int J Gynecol Cancer
; 31(6): 875-882, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33931498
11.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Int J Gynecol Cancer
; 31(10): 1348-1355, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34462317
12.
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
J Transl Med
; 18(1): 405, 2020 10 21.
Artigo
Inglês
| MEDLINE | ID: mdl-33087150
13.
The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.
J Transl Med
; 17(1): 148, 2019 05 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31077205
14.
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
Gynecol Oncol
; 154(1): 83-88, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31029508
15.
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
Gynecol Oncol
; 153(3): 535-540, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30979589
16.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 474-485, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29482983
17.
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
Gynecol Oncol
; 144(2): 256-259, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-27993479
18.
Angiogenesis Inhibitors in NSCLC.
Int J Mol Sci
; 18(10)2017 Sep 21.
Artigo
Inglês
| MEDLINE | ID: mdl-28934120
19.
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Lancet Oncol
; 17(8): 1137-1146, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27402147
20.
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
J Transl Med
; 19(1): 442, 2021 Oct 21.
Artigo
Inglês
| MEDLINE | ID: mdl-34674735